PRESSEFACH
WEITERE ADHOC-MELDUNGEN
Veröffentlichung einer Kapitalmarktinformation
Steubing AG - Hauptversammlung - Abstimmungsergebnisse im Überblick
Interview mit Vorstandsvorsitzendem Dr. Hannspeter Schubert
Vorstand beschließt Erhöhung und Verlängerung des laufenden Aktienrückkaufprogramms
STOCKHOLM IT VENTURES AB ERNENNT DEN MUSIKSTAR RONAN KEATING ALS MARKEN-BOTSCHAFTER
Advantag - Tochtergesellschaft heißt nun Auximio AG - Eintragung einer Kapitalerhöhung zwischenzeitlich durchgeführt
Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
 
MELDUNG VOM 04.10.2017 07:30
Meldung drucken Artikel weiterleiten
pta20171004006
Business news for the stock market
Pressefach Pressefach

Medigene: Medigene announces participation at four upcoming scientific and business development conferences

Planegg (pta006/04.10.2017/07:30) - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at four upcoming scientific and business development conferences:

3rd ACTC Advances in Circulating Tumour Cells
Date: 4 - 7 October 2017
Location: Rhodes, Greece

Immune Profiling Congress 2017
Date: 10 - 12 October 2017
Location: Barcelona, Spain
Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation on 11 October at 8.40 am on the topic: "Development of TCR-based adoptive T cell therapies: opportunities and challenges".

BIO Japan
Date: 11 - 13 October 2017
Location: Yokohama, Japan

DECHEMA colloquium: Trading in cells - Lab cultures, patients, and the promise of applications
Date: 18 October 2017
Location: Berlin, Germany
Dr. Kai Pinkernell, Chief Medical Officer of Medigene, will give a presentation at 2.15 pm on the topic "Transformation of a biotech company to a developer of innovative cell-based therapeutics".

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(Ende)

Aussender: Medigene
Lochhamer Straße 11
82152 Planegg
Deutschland
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail:
Website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Medigene
AKTUELLE BUSINESS NEWS
18.12.2017 09:10
Detektiv Sturm erweitert Geschäftsfeld
thurnhofer.cc
18.12.2017 06:00
Vorgesetzte am Handy kosten Vertrauen und Sinn
pressetext.redaktion
15.12.2017 13:52
Kryptowährung Bitcoin jetzt 18.000 Dollar wert
pressetext.redaktion
15.12.2017 06:15
Avatar als Lustobjekt aus VR-Headsets gelöscht
pressetext.redaktion
14.12.2017 15:00
Bilanz 2016: "Unsere Strategie ist aufgegangen"
DSER - Deutsche Software Engineering & Research GmbH
Weitere News anzeigen